Cargando…
Associations of HER2 Mutation With Immune-Related Features and Immunotherapy Outcomes in Solid Tumors
BACKGROUND: HER2 is one of the most extensively studied oncogenes in solid tumors. However, the association between tumor microenvironment (TME) and HER2 mutation remains elusive, and there are no specific therapies for HER2-mutated tumors. Immune checkpoint inhibitors (ICIs) have been approved for...
Autores principales: | Wang, Deqiang, Chen, Xiaofeng, Du, Yian, Li, Xiaoqin, Ying, Leqian, Lu, Yi, Shen, Bo, Gao, Xuan, Yi, Xin, Xia, Xuefeng, Sui, Xinbing, Shu, Yongqian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905508/ https://www.ncbi.nlm.nih.gov/pubmed/35281032 http://dx.doi.org/10.3389/fimmu.2022.799988 |
Ejemplares similares
-
Manipulating T-cell metabolism to enhance immunotherapy in solid tumor
por: Chen, Chen, et al.
Publicado: (2022) -
Editorial: Targeting metabolism to activate T cells and enhance the efficacy of checkpoint blockade immunotherapy in solid tumors
por: Xia, Zhijia, et al.
Publicado: (2023) -
Targeting KRAS(G12V) mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors
por: Ai, Qi, et al.
Publicado: (2023) -
The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer
por: Zeng, Hao, et al.
Publicado: (2022) -
A Pan-Cancer Analysis of Predictive Methylation Signatures of Response to Cancer Immunotherapy
por: Xu, Bingxiang, et al.
Publicado: (2021)